{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:50:29Z","timestamp":1787878229893,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1007\/s13318-013-0133-1","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T12:08:56Z","timestamp":1370002136000},"page":"43-52","source":"Crossref","is-referenced-by-count":42,"title":["The effect of mirabegron, a potent and selective \u03b23-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol"],"prefix":"10.1007","volume":"39","author":[{"given":"Walter","family":"Krauwinkel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marloes","family":"Schaddelee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Tretter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"van de Wetering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Strabach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"van Gelderen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,1]]},"reference":[{"key":"133_CR1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.clpt.2005.09.001","volume":"78","author":"RE Aarnoutse","year":"2005","unstructured":"Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw D, Wieling J, Hekster YA, Burger DM (2005) Effect of low-dose ritonavir (100\u00a0mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther 78:664\u2013674","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00004714-199708000-00008","volume":"17","author":"J Alderman","year":"1997","unstructured":"Alderman J, Preskorn SH, Greenblatt DJ, Harrison W, Penenberg D, Allison J, Chung M (1997) Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 17:284\u2013291","journal-title":"J Clin Psychopharmacol"},{"key":"133_CR3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.5414\/CP201782","volume":"50","author":"C Eltink","year":"2012","unstructured":"Eltink C, Lee J, Schaddelee MP, Zhang W, Meijer J, van Marle S, Grunenberg N (2012) Single dose pharmacokinetics and absolute bioavailability of mirabegron, a selective and potent \u03b23-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther 50:838\u2013850","journal-title":"Int J Clin Pharmacol Ther"},{"key":"133_CR4","unstructured":"European Medicines Agency (2010) Draft Guideline on the Investigation of Drug Interactions. http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/05\/WC500090112.pdf . Accessed 28 January 2013"},{"key":"133_CR5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00008571-199410000-00005","volume":"4","author":"B Evert","year":"1994","unstructured":"Evert B, Griese EU, Eichelbaum M (1994) Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 4:271\u2013274","journal-title":"Pharmacogenetics"},{"key":"133_CR6","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.2010.03731.x","volume":"70","author":"I Gueorguieva","year":"2010","unstructured":"Gueorguieva I, Jackson K, Wrighton SA, Sinha VP, Chien JY (2010) Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug\u2013drug interaction trials. Br J Clin Pharmacol 70:523\u2013536","journal-title":"Br J Clin Pharmacol"},{"key":"133_CR7","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1067\/mcp.2000.106464","volume":"67","author":"BA Hamelin","year":"2000","unstructured":"Hamelin BA, Bouayad A, M\u00e9thot J, Jobin J, Desgagn\u00e9s P, Poirier P, Allaire J (2000) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clin Pharmacol Ther 67:466\u2013477","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00228-006-0129-8","volume":"63","author":"RZ Harris","year":"2007","unstructured":"Harris RZ, Salfi M, Posvar E, Hoelscher D, Padhi D (2007) Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol 63:159\u2013163","journal-title":"Eur J Clin Pharmacol"},{"key":"133_CR9","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/0140-6736(90)92086-W","volume":"336","author":"M Heim","year":"1990","unstructured":"Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529\u2013532","journal-title":"Lancet"},{"key":"133_CR10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mcp.2000.104788","volume":"67","author":"A Hemeryck","year":"2000","unstructured":"Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM (2000) Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 67:283\u2013291","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00008571-199608000-00008","volume":"6","author":"I Johansson","year":"1996","unstructured":"Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351\u2013355","journal-title":"Pharmacogenetics"},{"key":"133_CR12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","volume":"63","author":"V Khullar","year":"2013","unstructured":"Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, Radziszewski P, Rechberger T, Boerrigter P, Drogendijk T, Wooning M, Chapple C (2013) Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a Randomised European-Australian Phase 3 Trial. Eur Urol 63:283\u2013295. doi: 10.1016\/j.eururo.2012.10.016","journal-title":"Eur Urol"},{"key":"133_CR13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00228-003-0714-z","volume":"59","author":"K Laine","year":"2004","unstructured":"Laine K, De Bruyn S, Bj\u00f6rklund H, Rouru J, H\u00e4nninen J, Scheinin H, Anttila M (2004) Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Eur J Clin Pharmacol 59:893\u2013898","journal-title":"Eur J Clin Pharmacol"},{"key":"133_CR14","doi-asserted-by":"crossref","unstructured":"Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J. Role of Cytochrome P450 Isoenzymes 3A and 2D6 in the in Vivo Metabolism of Mirabegron, a \u03b23-adrenoceptor agonist. Clin Drug Invest. 2013 (Accepted)","DOI":"10.1007\/s40261-013-0084-y"},{"key":"133_CR15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/00498258609050250","volume":"16","author":"MS Lennard","year":"1986","unstructured":"Lennard MS, Tucker GT, Silas JH, Woods HF (1986) Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 16:435\u2013447","journal-title":"Xenobiotica"},{"key":"133_CR16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1365-2125.1985.tb05112.x","volume":"20","author":"JC McGourty","year":"1985","unstructured":"McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism\u2014population and family studies. Br J Clin Pharmacol 20:555\u2013566","journal-title":"Br J Clin Pharmacol"},{"key":"133_CR17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0091270008326716","volume":"49","author":"AI Nichols","year":"2009","unstructured":"Nichols AI, Fatato P, Shenouda M, Paul J, Isler JA, Pedersen RD, Jiang Q, Ahmed S, Patroneva A (2009) The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults. J Clin Pharmacol 49:219\u2013228","journal-title":"J Clin Pharmacol"},{"key":"133_CR18","doi-asserted-by":"crossref","unstructured":"Nitti V, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S (2012) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. doi: 10.1016\/j.juro.2012.10.017 (Epub ahead of print)","DOI":"10.1016\/j.juro.2012.10.017"},{"key":"133_CR19","first-page":"90","volume":"14","author":"SH Preskorn","year":"1994","unstructured":"Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S (1994) Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 14:90\u201398","journal-title":"J Clin Psychopharmacol"},{"key":"133_CR20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.2165\/00003088-199018050-00002","volume":"18","author":"FR Sallee","year":"1990","unstructured":"Sallee FR, Pollock BG (1990) Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 18:346\u2013364","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"133_CR21","first-page":"S21","volume":"89","author":"T Sawamoto","year":"2011","unstructured":"Sawamoto T, Lee J, Alak A et al (2011) Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther 89(Suppl 1):S21","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/clpt.1985.235","volume":"38","author":"B Schmid","year":"1985","unstructured":"Schmid B, Bircher J, Preisig R, K\u00fcpfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618\u2013624","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00007691-199306000-00011","volume":"15","author":"E Spina","year":"1993","unstructured":"Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP (1993) Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 15:243\u2013246","journal-title":"Ther Drug Monit"},{"key":"133_CR24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF02246212","volume":"117","author":"E Spina","year":"1995","unstructured":"Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E (1995) The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology 117:413\u2013416","journal-title":"Psychopharmacology"},{"key":"133_CR25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00007691-199602000-00010","volume":"18","author":"E Spina","year":"1996","unstructured":"Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E (1996) Phenobarbital induces the 2-hydroxylation of desipramine. Ther Drug Monit 18:60\u201364","journal-title":"Ther Drug Monit"},{"key":"133_CR26","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/clinchem\/44.5.914","volume":"44","author":"LS Steijns","year":"1998","unstructured":"Steijns LS, Van Der Weide J (1998) Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 44:914\u2013917","journal-title":"Clin Chem"},{"key":"133_CR27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/clpt.1987.147","volume":"42","author":"E Steiner","year":"1987","unstructured":"Steiner E, Spina E (1987) Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 42:278\u2013282","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0091270010365559","volume":"51","author":"SM Stout","year":"2011","unstructured":"Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, Bleske BE (2011) Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. J Clin Pharmacol 51:389\u2013396","journal-title":"J Clin Pharmacol"},{"key":"133_CR29","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","volume":"321","author":"T Takasu","year":"2007","unstructured":"Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2019-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642\u2013647. doi: 10.1124\/jpet.106.115840","journal-title":"J Pharmacol Exp Ther"},{"key":"133_CR30","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","volume":"42","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa S, Scheinkoenig J, Buckley D, Miyashita A, Iwatsubo T, Usui T (2012a) In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective \u03b23-adrenoceptor agonist. Xenobiotica 42:1187\u20131196","journal-title":"Xenobiotica"},{"key":"133_CR31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.111.043588","volume":"40","author":"S Takusagawa","year":"2012","unstructured":"Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T (2012b) Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 40:815\u2013824","journal-title":"Drug Metab Dispos"},{"key":"133_CR32","doi-asserted-by":"crossref","unstructured":"Takusagawa S, Yajima K, Miyashita A, Iwatsubo T, Usui T (2012c) Identification of human CYP isoforms and esterases involved in the metabolism of mirabegron (YM178), a novel selective \u03b23-adrenoceptor agonist. Xenobiotica 42(10):957\u2013967","DOI":"10.3109\/00498254.2012.675095"},{"key":"133_CR33","unstructured":"US Food and Drug Administration (2012) Draft guidance for industry on drug interaction studies\u2014study design, data analysis, implications for dosing and labeling recommendations. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM292362.pdf . Accessed 28 January 2013"},{"issue":"Suppl 1","key":"133_CR34","first-page":"S88","volume":"85","author":"E Gelderen van","year":"2009","unstructured":"van Gelderen E, Li Q, Meijer J, Schaddelee MP, Takusagawa S, Sugawara T, de Koning P (2009) An exploratory comparison of the single dose pharmacokinetics of the \u03b23-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther 85(Suppl 1):S88","journal-title":"Clin Pharmacol Ther"},{"key":"133_CR35","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/00007691-200008000-00020","volume":"22","author":"J Wieling","year":"2000","unstructured":"Wieling J, Tamminga WJ, Sakiman EP, Oosterhuis B, Wemer J, Jonkman JH (2000) Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening. Ther Drug Monit 22:486\u2013496","journal-title":"Ther Drug Monit"},{"key":"133_CR36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.5414\/CPP39037","volume":"39","author":"KH Yuen","year":"2001","unstructured":"Yuen KH, Wong JW, Yap SP, Billa N (2001) Estimated coefficient of variation values for sample size planning in bioequivalence studies. Int J Clin Pharmacol Ther 39:37\u201340","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-013-0133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-013-0133-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-013-0133-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T12:14:47Z","timestamp":1595852087000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-013-0133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["133"],"URL":"https:\/\/doi.org\/10.1007\/s13318-013-0133-1","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,1]]}}}